Illumina Inc
NASDAQ:ILMN

Watchlist Manager
Illumina Inc Logo
Illumina Inc
NASDAQ:ILMN
Watchlist
Price: 140.14 USD 2.3% Market Closed
Market Cap: 22.2B USD
Have any thoughts about
Illumina Inc?
Write Note

Illumina Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Illumina Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Illumina Inc
NASDAQ:ILMN
Accrued Liabilities
$422m
CAGR 3-Years
3%
CAGR 5-Years
14%
CAGR 10-Years
2%
Thermo Fisher Scientific Inc
NYSE:TMO
Accrued Liabilities
$5.2B
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
12%
Danaher Corp
NYSE:DHR
Accrued Liabilities
$2.9B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
1%
Mettler-Toledo International Inc
NYSE:MTD
Accrued Liabilities
$364.6m
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Accrued Liabilities
$573m
CAGR 3-Years
-8%
CAGR 5-Years
5%
CAGR 10-Years
-2%
IQVIA Holdings Inc
NYSE:IQV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Illumina Inc
Glance View

Market Cap
22.3B USD
Industry
Life Sciences Tools & Services

Illumina Inc. is a pioneering biotechnology company that has revolutionized the field of genomics by developing advanced sequencing technologies that unveil the secrets of the human genome. Founded in 1998 and based in San Diego, California, Illumina has positioned itself at the forefront of genetic research, providing scientists and clinicians with tools that enhance disease detection, treatment options, and personalized medicine. With a commitment to innovation, Illumina’s sequencers have made genetic sequencing faster, cheaper, and more accessible—empowering researchers to explore the genetic underpinnings of health and disease like never before. Their flagship products, such as the NovaSeq and NextSeq series, are instrumental in various applications, from cancer research and reproductive health to infectious disease surveillance. For investors, Illumina represents a unique opportunity in the rapidly expanding biotechnology sector. The company’s robust growth trajectory is underpinned by strategic partnerships with leading research institutions and pharmaceutical companies, fostering a collaborative ecosystem in genomic research and diagnostics. Illumina's strong financial performance is reflected in its consistent revenue growth and expanding market share, making it a formidable player in the global healthcare landscape. As the demand for precision medicine rises and genomic data becomes increasingly integral to modern healthcare, Illumina is poised to capture significant market opportunities. With a focus on innovation, evolving technologies, and a long-term vision for enhancing human health through genomics, Illumina remains a compelling investment proposition in an era where genetic insights are paramount.

ILMN Intrinsic Value
140.23 USD
Fairly Valued
Intrinsic Value
Price

See Also

What is Illumina Inc's Accrued Liabilities?
Accrued Liabilities
422m USD

Based on the financial report for Sep 29, 2024, Illumina Inc's Accrued Liabilities amounts to 422m USD.

What is Illumina Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
2%

Over the last year, the Accrued Liabilities growth was -55%. The average annual Accrued Liabilities growth rates for Illumina Inc have been 3% over the past three years , 14% over the past five years , and 2% over the past ten years .

Back to Top